UNICREDIT BANK/CALL/ELI LILLY & CO/1125/0.1/18.06.25 Share Price

Warrant

DE000HD4PE56

Real-time BOERSE MUENCHEN 20:42:15 24/05/2024 BST
3.31 EUR -0.30% Intraday chart for UNICREDIT BANK/CALL/ELI LILLY & CO/1125/0.1/18.06.25
Current month+11.07%
1 month+46.46%
Date Price Change
24/05/24 3.31 -0.30%
23/05/24 3.32 +7.10%
22/05/24 3.1 -0.96%
21/05/24 3.13 +19.01%
20/05/24 2.63 +4.37%

Real-time BOERSE MUENCHEN

Last update May 24, 2024 at 08:42 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
IssuerLogo Issuer UniCredit UniCredit
WKN HD4PE5
ISINDE000HD4PE56
Date issued 16/04/2024
Strike 1,125 $
Maturity 18/06/2025 (388 Days)
Parity 10 : 1
Emission price 2.92
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.32
Lowest since issue 2.05
Delta0.25x
Omega 5.765
Premium43.7x
Gearing22.87x
Moneyness 0.7177
Difference Strike 317.6 $
Difference Strike %+28.23%
Spread 0.11
Spread %3.32%
Theoretical value 3.255
Implied Volatility 32.89 %
Total Loss Probability 84.21 %
Intrinsic value 0.000000
Present value 3.255
Break even 1,160.31 €
Theta-0.09x
Vega0.24x
Rho0.17x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4 USD
Average target price
850.8 USD
Spread / Average Target
+5.37%
Consensus